Skip to main
NDRA

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences Inc. is positioned for substantial growth as it anticipates FDA approval for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology within the next year, which could significantly enhance its stock performance. The company’s product is projected to offer a more accurate and cost-effective method for diagnosing and monitoring Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), addressing a major healthcare need for over one billion affected individuals globally. Additionally, a net present value (NPV) analysis suggests there is considerable upside potential from the current share price, reinforcing a positive outlook on the company's financial trajectory.

Bears say

ENDRA Life Sciences Inc reported a net loss of $1.6 million or EPS of $(2.10), which was worse than the estimated EPS of $(1.95), indicating ongoing financial challenges. Additionally, the firm faces multiple significant risks, including liquidity issues, potential failure in clinical trials, and hurdles related to regulatory approvals and product commercialization, which could impede its market prospects. The continuous negative financial performance alongside these substantial risks highlights a concerning outlook for the firm's ability to achieve favorable market conditions and investor confidence.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.